Frontiers in Virology, published by FRONTIERS MEDIA SA, is an innovative open-access journal dedicated to advancing the understanding of viral biology, pathogenesis, surveillance, and control strategies. With the rapid evolution of viral threats, this journal serves as a critical platform for researchers, professionals, and students to disseminate and access high-quality research, reviews, and perspectives in virology. The journal places a strong emphasis on interdisciplinary approaches, promoting collaborative efforts that drive breakthroughs in the field. While the specific impact factor and H-index details are currently unavailable, Frontiers in Virology is committed to rigorous peer review and integrity in scientific publishing. Authors and readers will benefit from the extensive reach provided by open access, making groundbreaking insights available to a global audience, thus contributing significantly to the ongoing dialogue in virology and public health.

Infectious Agents and Cancer is a pivotal open access journal published by BMC, dedicated to advancing research at the intersection of infectious diseases and oncology. Since its inception in 2006, this journal has provided a platform for the exploration of the complex relationships between infectious agents and cancer development, aimed at researchers, healthcare professionals, and students alike. With a broad scope encompassing epidemiology and cancer research, the journal holds an impressive ranking in the Q3 quadrant for epidemiology, infectious diseases, and oncology in 2023, while also featuring in the Q4 category for cancer research. This distinguished journal not only contributes to the enrichment of scientific knowledge but also fosters collaborative efforts towards innovative solutions in the fight against cancer. Being part of the UK publishing landscape, the journal is accessible to a global audience, ensuring that vital research findings are disseminated widely to inform policy and practice in health sciences.

Viral Immunology, published by Mary Ann Liebert, Inc, stands as a prominent journal dedicated to advancing the understanding of the interplay between viral infections and host immune responses. With a strong focus on immunology, molecular medicine, and virology, the journal provides a platform for the dissemination of high-quality research findings and innovative methodologies that could shape the future of these critical fields. Although it currently holds a Q3 rating across its relevant categories and a respectable ranking within the Scopus database, Viral Immunology continues to strive for excellence with a commitment to publishing influential research that informs both academic and clinical practices. The journal accepts submissions in various formats—original research, reviews, and commentaries—catering to a diverse readership that includes researchers, professionals, and students engaged in the biological and medical sciences. Readers can anticipate insightful articles that address urgent challenges in immunological responses to viral infections, paving the way for new therapeutic strategies and public health initiatives.

Journal of Virology is a premier scholarly journal dedicated to advancing the field of virology, focusing on the molecular mechanisms of virus-host interactions, viral pathogenesis, and the latest therapeutic and vaccine developments. Published by the American Society for Microbiology, this esteemed journal has been a cornerstone for researchers since its inception in 1967, providing a platform for high-quality, peer-reviewed research. With a commendable impact factor indicative of its relevance and influence, the journal is categorized in the top quartile (Q1) for Virology, Microbiology, and Insect Science, reflecting its significance in these fields. Researchers can access a wealth of studies and findings that shape our understanding of viruses and their interactions with hosts, highlighting its role in both basic and applied sciences. Positioned in the United States, the Journal of Virology serves a global audience, ensuring that cutting-edge discoveries reach professionals, students, and academics alike. Join the conversation as we explore the complexities of virology and its implications for human health and disease.

Human Vaccines & Immunotherapeutics, published by TAYLOR & FRANCIS INC, stands at the forefront of immunology and vaccine research, presenting critical advancements and innovative approaches to immunotherapy since its inception in 2012. With an impressive impact factor and rankings in the top quartiles of leading categories such as Immunology, Pharmacology, and Medicine, this journal serves as a vital resource for researchers, healthcare professionals, and students who are dedicated to advancing the understanding and application of vaccines and immunotherapeutic strategies. Offering Open Access options for enhanced visibility and outreach, the journal encourages the dissemination of high-quality research that can drive meaningful impact in public health. Its continuous commitment to excellence is reflected in its ranking metrics—ranking #71 in Pharmacology with a 77th percentile and #69 in Immunology and Allergy with a 70th percentile, ensuring that it remains a preferred forum for notable scholarly contributions in a rapidly evolving field.

Clinical and Experimental Vaccine Research, an esteemed journal published by the Korean Vaccine Society, serves as a vital platform for disseminating groundbreaking research in the fields of Immunology, Infectious Diseases, and Public Health. Since its inception in 2012, this open-access journal has been committed to advancing knowledge and fostering collaboration among professionals dedicated to vaccine development and evaluation. With an impactful presence and a Q3 ranking in several categories on the Scopus index, it reflects a robust commitment to quality, evidenced by its placement within the 41st to 59th percentiles across multiple disciplines related to medicine and health. Situated in Seoul, South Korea, at the Department of Pediatrics, Yonsei University Severance Children's Hospital, the journal not only provides a crucial resource for researchers and practitioners but also enhances the global discourse on vaccination strategies and public health interventions. By contributing to the ongoing dialogue in vaccine research, this journal plays an essential role in shaping future health policies and practices.

BIOLOGICALS, published by Academic Press Ltd - Elsevier Science Ltd, is a prestigious journal dedicated to advancing the fields of applied microbiology, biotechnology, immunology, and pharmacology. With an ISSN of 1045-1056 and E-ISSN of 1095-8320, this journal has established itself as a vital resource for researchers and practitioners, offering rigorous peer-reviewed content that spans converging disciplines from 1990 to 2024. With a commendable presence in the field, it ranks in the Q3 category across multiple domains, including applied microbiology and biotechnology, highlighting its contribution to critical advancements and knowledge dissemination. The journal's rankings reflect its relevance, with notable placements in Scopus Ranks, ensuring it remains an important platform for innovative research and discussion. Although it does not currently offer Open Access, the journal’s comprehensive review process guarantees the quality of published work, making it essential reading for professionals, academics, and students seeking to stay informed about the latest developments in biology and life sciences.

REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO is a prestigious open-access journal that has been publishing significant research in the field of tropical medicine since its inception in 1961. Produced by the Instituto de Medicina Tropical de São Paulo, the journal boasts a commendable Q3 ranking in both the categories of Infectious Diseases and Medicine (miscellaneous), as per the latest 2023 metrics. With an ISSN of 0036-4665 and E-ISSN of 1678-9946, it serves as a prominent platform for scholars and professionals to disseminate their findings and insights on pressing health issues prevalent in tropical regions, particularly those relevant to Brazil and beyond. This journal is essential for researchers and practitioners who seek to advance their understanding and apply innovative solutions in tropical medicine, thus addressing the distinct challenges posed by infectious diseases in diverse populations. The journal is accessible through various open access platforms, ensuring that critical research is available to a global audience, fostering knowledge sharing and collaboration.

AIMS Allergy and Immunology is a prestigious open access journal dedicated to advancing knowledge in the fields of allergy and immunology. Published by the American Institute of Mathematical Sciences (AIMS), this journal provides a vibrant platform for researchers, practitioners, and scholars to share groundbreaking findings and insights. Recognized for its commitment to disseminating high-quality research since its inception in 2017, AIMS Allergy and Immunology contributes significantly to the understanding of complex immunological mechanisms and allergic responses, thus playing a pivotal role in enhancing clinical practices and therapeutic strategies. With its ISSN 2575-615X, the journal aims to facilitate a robust exchange of ideas and promote collaboration within the scientific community. Researchers and practitioners are encouraged to access the latest studies and reviews, which are all freely available online, ensuring that vital information reaches a global audience without barriers. Together, we can tackle the challenges posed by allergies and immune disorders through rigorous scientific inquiry and innovation.

Vaccine: X, published by Elsevier, is a premier open access journal dedicated to advancing research in the interdisciplinary fields of immunology and microbiology, infectious diseases, molecular medicine, and public health. With an ISSN of 2590-1362 and operating since 2019, the journal has rapidly established an influential role, achieving Q2 rankings in major categories such as Immunology and Microbiology, Infectious Diseases, and Public Health for 2023. Its commitment to disseminating cutting-edge research is evident from its broad scope, focusing on innovative vaccines and therapies that are critical for global health. Researchers and professionals will find value in the accessible nature of the journal, which has been recognized for its contributions to veterinary medicine as well, with a Q1 ranking in the miscellaneous veterinary category. The journal proudly showcases high-quality, peer-reviewed articles and welcomes submissions that push the boundaries of current knowledge, making it an essential resource for anyone involved in vaccine research and development.